# A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial

> **NCT02208063** · PHASE3 · TERMINATED · sponsor: **Cumberland Pharmaceuticals** · enrollment: 121 (actual)

## Conditions studied

- Bacteremia

## Interventions

- **DRUG:** Telavancin
- **DRUG:** Vancomycin
- **DRUG:** Daptomycin
- **DRUG:** Synthetic penicillin
- **DRUG:** Cefazolin

## Key facts

- **NCT ID:** NCT02208063
- **Lead sponsor:** Cumberland Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-12
- **Primary completion:** 2018-04-12
- **Final completion:** 2018-04-12
- **Target enrollment:** 121 (ACTUAL)
- **Why stopped:** Halted due to lack of statistical power. No safety concerns identified.
- **Last updated:** 2020-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02208063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02208063, "A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02208063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*